TransCode Therapeutics, Inc. Common Stock
RNAZStock
$8.27−4.67%52W
Market Cap$8.26M
P/E—
Div yield—
Beta1.21
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)8.70%
Price vs S&P 500 (4W)57.25%
VGM Score59.00
Market Capitalization$8.26M
Analyst Recommendations
Mar 2025
Apr 2025
May 2025
Jun 2025
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
RNAZTransCode Therapeutics, Inc. Common Stock | — | — | C | $8.27 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
TransCode Therapeutics is a biopharmaceutical company developing cancer therapeutics and diagnostics. The company's lead candidate, TTX-MC138, is a nanoparticle-conjugated oligonucleotide in clinical development designed to inhibit metastatic tumor survival. If approved, the therapy aims to achieve durable disease regression and improve long-term patient survival outcomes.